TY - CHAP
T1 - Effects of hyperoxia on the developing airway and pulmonary vasculature
AU - Pabelick, Christina M
AU - Thompson, Michael A.
AU - Britt, Rodney Jr.
PY - 2017
Y1 - 2017
N2 - Although it is necessary and part of standard practice, supplemental oxygen (40–90% O2) or hyperoxia is a significant contributing factor to development of bronchopulmonary dysplasia, persistent pulmonary hypertension, recurrent wheezing, and asthma in preterm infants. This chapter discusses hyperoxia and the role of redox signaling in the context of neonatal lung growth and disease. Here, we discuss how hyperoxia promotes dysfunction in the airway and the known redox-mediated mechanisms that are important for postnatal vascular and alveolar development. Whether in the airway or alveoli, redox pathways are important and greatly influence the neonatal lung.
AB - Although it is necessary and part of standard practice, supplemental oxygen (40–90% O2) or hyperoxia is a significant contributing factor to development of bronchopulmonary dysplasia, persistent pulmonary hypertension, recurrent wheezing, and asthma in preterm infants. This chapter discusses hyperoxia and the role of redox signaling in the context of neonatal lung growth and disease. Here, we discuss how hyperoxia promotes dysfunction in the airway and the known redox-mediated mechanisms that are important for postnatal vascular and alveolar development. Whether in the airway or alveoli, redox pathways are important and greatly influence the neonatal lung.
KW - Alveologenesis
KW - Heme oxygenase-1
KW - Hyperoxia
KW - Hypoxia inducible factor nitric oxide
KW - Lung development
KW - Nuclear factor E2-related factor 2
KW - Pulmonary vasculogenesis redox signaling
KW - Soluble guanylate cyclase
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85031997147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031997147&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-63245-2_11
DO - 10.1007/978-3-319-63245-2_11
M3 - Chapter
C2 - 29047087
AN - SCOPUS:85031997147
VL - 967
T3 - Advances in Experimental Medicine and Biology
SP - 179
EP - 194
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -